Text Size

Radiation Biodosimetry in Children Undergoing Total Body Irradiation

This study is currently recruiting participants.
Verified May 2013 by Medical College of Wisconsin
Sponsor:
Information provided by (Responsible Party):
John Baker, Medical College of Wisconsin
ClinicalTrials.gov Identifier:
NCT01337648
First received: March 2, 2011
Last updated: May 6, 2013
Last verified: May 2013
History of Changes
  Purpose

The purpose of this study is to develop fecal tests that will determine the extent of radiation exposure in patients undergoing radiation treatment for cancer. This project will determine whether fecal biomarkers can be used to diagnose exposure to radiation.


Condition
Total-body Irradiation
Hematopoietic Stem Cell Transplant

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Radiation Biodosimetry in Children Undergoing Total Body Irradiation

Resource links provided by NLM:

MedlinePlus related topics: Bowel Movement
U.S. FDA Resources

Further study details as provided by Medical College of Wisconsin:

Primary Outcome Measures:
  • To describe changes in gene expression associated with exposure to radiation [ Time Frame: prior to TBI treatment (baseline) and up to 2 weeks following the last dose of TBI ] [ Designated as safety issue: No ]
    Changes in gene expression will be measured as abundance of RNA levels relative to the weight of feces


Biospecimen Retention:   Samples With DNA

Stool


Estimated Enrollment: 20
Study Start Date: November 2010
Estimated Primary Completion Date: November 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts
TBI prior to stem cell transplantation

Detailed Description:

Patients undergoing TBI as part of a hematopoietic stem cell transplant (HSCT) will have feces collected for use in the validation and refinement of new methods for rapid radiation biodosimetry. The stool samples will be collected before, and at defined times after TBI. Stool sampling will occur in the same manner that it does during routine patient care during HSCT.

  Eligibility

Ages Eligible for Study:   2 Years to 21 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients undergoing Total Body Irradiation (TBI) preceding hematopoietic stem cell transplantation.

Criteria

Inclusion Criteria:

  • All races are eligible
  • 2 years to 21 years old
  • Must be undergoing hematopoietic stem cell transplantation (either autologous or allogeneic) in conjunction with a conditioning regimen that includes total-body irradiation (TBI) (single or multiple fraction).
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01337648

Contacts
Contact: John Baker, MD 414-456-8706 jbaker@mcw.edu
Contact: Kristine Allmendinger-Goertz, BA 414-266-2137 kallmend@mcw.edu

Locations
United States, Wisconsin
Children's Hospital of Wisconsin Recruiting
Milwaukee, Wisconsin, United States, 53226
Contact: John Baker, MD     414-456-8706     jbaker@mcw.edu    
Contact: Kristine Allmendinger-Goertz, BA     414-266-2137     kallmend@mcw.edu    
Principal Investigator: John Baker, MD            
Sponsors and Collaborators
Medical College of Wisconsin
Investigators
Principal Investigator: John Baker, MD Medical College of Wisconsin
  More Information

No publications provided

Responsible Party: John Baker, Professor of Surgery/Cardiothoracic/Research, Medical College of Wisconsin
ClinicalTrials.gov Identifier: NCT01337648     History of Changes
Other Study ID Numbers: RadBio-10/191
Study First Received: March 2, 2011
Last Updated: May 6, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by Medical College of Wisconsin:
Fecal biomarkers
Radiation biodosimetry
Total-body irradiation (TBI)
 Hematopoietic stem cell transplantation
Gene expression profiles
Fecal metabolites

ClinicalTrials.gov processed this record on May 16, 2013